Corrigendum: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.

Chaudhary, Sachin; Natt, Bhupinder; Bime, Christian; Knox, Kenneth S; Glassberg, Marilyn K

Chaudhary, Sachin; Natt, Bhupinder; Bime, Christian; Knox, Kenneth S; Glassberg, Marilyn K.

Afiliação

Chaudhary S; Interstitial Lung Disease Program, University of Arizona Colleges of Medicine, Tucson, AZ, United States.
Natt B; Interstitial Lung Disease Program, University of Arizona Colleges of Medicine, Tucson, AZ, United States.
Bime C; Interstitial Lung Disease Program, University of Arizona Colleges of Medicine, Tucson, AZ, United States.
Knox KS; Banner-University Medicine Division, Phoenix, AZ, United States.
Glassberg MK; Banner-University Medicine Division, Phoenix, AZ, United States.

Front Med (Lausanne) ; 7: 604640, 2020.

Article em En | MEDLINE | ID: mdl-33777966

ABSTRACT

ABSTRACT

[This corrects the article DOI 10.3389/fmed.2020.00539.].

Palavras-chave

ARDS; COVID - 19; MERS (Middle East respiratory syndrome); SARS; SARS - CoV-2; antifibrotics; fibrosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google